Pharmaceuticals, Biotechnology and Life Sciences
– Total revenue of $131 million, driven primarily by LINZESS® (linaclotide) U.S. collaboration revenue of $85 million and ex-U.S. license…
BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will…
Analyses of tebentafusp data provide further insight into platform’s mechanism of action, potential link to clinical activity in uveal melanoma…
Highly statistically significant activity relative to vehicle across every assessed symptom and sign observed in allergen chamber clinical trial Agreement…
Successful conclusion of an End of Phase II meeting with the FDA PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE MKT:…
Increases Third Quarter Revenues 6% to $6.0 Billion Posts Third Quarter GAAP EPS of $0.83 and Non-GAAP EPS of $1.17…
– Roche to gain worldwide license to Dicerna’s novel RNAi therapy currently in Phase 1 – – Dicerna to receive…
– Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 – VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia…
Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net…
DUBLIN–(BUSINESS WIRE)–The “Antibiotic Resistance Markets – Therapeutics By Pathogen and Therapy Type 2020 To 2024” report has been added to…